Work

Nelarabine Combination Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Lymphoma/Leukemia

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-157545

Authors: Shai Shimony, Yiwen Liu, Yannis K. Valtis, Jonathan D. Paolino, Andrew E. Place, Andrew M. Brunner, Lachelle D. Weeks, Lewis B. Silverman, Lynda M. Vrooman, Donna S. Neuberg, Richard M. Stone, Daniel J. DeAngelo, Marlise R. Luskin

Institutions: Tel Aviv University, Rabin Medical Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard University, Massachusetts General Hospital

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310125611

FWCI: 0.404

Cites:

Cited by: 2

Related to: 10